Biosimilar competition significantly reduces out-of-pocket costs for Medicare patients, enhancing affordability for biologic ...
Explore the complexities of insulin biosimilars, their safety, and the impact on diabetes management in global health systems ...
Denosumab biosimilars enhance treatment access for postmenopausal osteoporosis, demonstrating equivalent efficacy and safety ...
Australia's biosimilar adoption significantly reduces biologic medicine costs, enhancing access while maintaining utilization ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive ...
Amgen’s Amjevita (adalimumab-atto) has officially entered the US market, making it the first of potentially 10 biosimilars referencing Humira to launch in 2023. Amgen has launched Amjevita (adalimumab ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback